Welcome!

.NET Authors: Adine Deford, Srinivasan Sundara Rajan, David Fletcher, Pat Romanski, Tad Anderson

News Feed Item

Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting

SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal 2013 first quarter ended September 30, 2012.

Financial Results for First Quarter Ended September 30, 2012

The GAAP (Generally Accepted Accounting Principles) net income for the fiscal quarter ended September 30, 2012 was $75.6 million, or $1.09 and $1.02 per basic and diluted earnings per share, respectively. This compares with a GAAP net loss of $14.5 million, or $0.21 loss per basic and diluted share for the fiscal quarter ended September 30, 2011.

The non-GAAP net income reported for the fiscal quarter ended September 30, 2012 was $78.8 million, or $1.14 and $1.07 income per basic and diluted earnings per share, respectively. This compares with a non-GAAP net loss of $12.4 million, or $0.18 basic and diluted loss per share, for the fiscal quarter ended September 30, 2011. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

Revenue for the fiscal quarter ended September 30, 2012 was $102.7 million, compared to $37,000 for the fiscal quarter ended September 30, 2011, an increase of approximately $102.7 million. Revenue for the fiscal quarter ended September 30, 2012 consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. ("Janssen").

At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million, which compares with $203.6 million at June 30, 2012. Total operating expenses excluding share based compensation during the quarter ending September 30, 2012 were $20.8 million compared to $17.8 million during the quarter ending June 30, 2012. The Company also had $8.6 million due from Janssen at September 30, 2012 in connection with the Agreement. Additionally, as announced on October 15, 2012, the Company triggered a $50 million milestone payment obligation from Janssen under the Agreement as a result of the enrollment of a fifth patient in a study of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. The Company received the $50 million milestone payment from Janssen in October 2012.

To date, the Company has received three milestone payments from Janssen of $50 million each under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

On October 4, 2012, the Company entered into a strategic license agreement with Novo Nordisk A/S. Novo Nordisk acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology. Novo Nordisk will utilize PCI-27483 as an excipient in a product within Novo Nordisk's biopharmaceutical unit. In connection with entering into this agreement, the Company is entitled to an upfront payment of $5 million which was received in October 2012. In addition, the Company may receive up to $55 million based on the achievement of certain development, regulatory and sales milestones. Upon commercialization, the Company will also receive low single digit tiered royalties on Novo Nordisk net sales of biopharmaceutical formulations utilizing the addition of PCI-27483.

Recent Developments & Highlights

Nine Oral Presentations and Seven Poster Presentations for our BTK Inhibitor Ibrutinib (PCI-32765) and one Oral Presentation and one Poster Presentation for our HDAC Inhibitor Abexinostat (PCI-24781) have been accepted at the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA (December 8-11, 2012).  These abstracts will be published today on the ASH website at www.hematology.org at approximately 10:00 a.m. ET. They are showing overall clinical and pre-clinical progress in many programs to date. Clinical presentations scheduled during the ASH annual meeting in December will provide further updates to these abstracts regarding the efficacy and safety of ibrutinib (PCI-32765), particularly in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma.

Early Phase I data in follicular lymphoma and Phase II data in diffuse large b-cell lymphoma (DLBCL) will also be provided at ASH. As the clinical path for DLBCL will continue to evolve further, we expect to provide additional color in the second half of 2013. We are also reporting on a first, small cohort of multiple myeloma (MM) patients. We learned that single agent ibrutinib at 420 mg is tolerable to administer but did not produce defined objective responses (PR, CRs) at this dose. There were, however, several patients that achieved stable disease and minor response. We have expanded the program to understand the drug's response at higher doses (560 mg and 840 mg) and in combination with dexamethasone at the 560 mg and potentially 840 mg dose. As we obtain further data from these cohorts over the next 12 months, we will assess the clinical outcome of ibrutinib in this patient population. At this time, we do not expect to further evaluate single agent ibrutinib at the 420 mg dose in MM.  

Additionally, the investigation of ibrutinib (PCI-32765) for the treatment of patients with CLL/SLL who have relapsed or have refractory disease and have previously received at least one prior therapy was designated as a Fast Track Development Program by the Division of Hematology Products, Office of Hematology and Oncology Products, a department of the FDA.

An update to the ASH published abstracts and progress on our clinical trials will be provided in a conference call following the ASH presentations on December 12, 2012. Until that time, we will adhere to the ASH embargo and not discuss the ASH presentations further in public.

Clinical ASH Presentations for BTK Inhibitor Ibrutinib (PCI-32765)

  • Mantle Cell Lymphoma Oral Presentation
    Title: Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL):  Durable Efficacy and Tolerability with Longer Follow-up
    Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Optimizing Current Treatment Strategies
    Date/Time: Tuesday, December 11, 2012 Presentation Time8:15 AM
    Location: Georgia World Congress Center, B405-B407
    Presenter: Michael (Luhua) Wang
  • Chronic Lymphocytic Leukemia Oral Presentation
    Title: The Btk inhibitor Ibrutinib in combination with rituximab is well tolerated and displays profound activity in high-risk Chronic Lymphocytic Leukemia (CLL) patients
    Session: 642. CLL - Therapy, excluding Transplantation: New Targeted Therapies  
    Date/Time: Sunday, December 9, 2012   Presentation Time4:30 PM
    Location: Georgia World Congress Center, Thomas Murphy Ballroom 4
    Presenter: Jan Burger
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Oral Presentation
    Title: The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) CLL or SLL Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study
    Session: 642. CLL - Therapy, excluding Transplantation: New Targeted Therapies
    Date/Time: Sunday, December 9, 2012   Presentation Time5:00 PM
    Location: Georgia World Congress Center, Thomas Murphy Ballroom 4
    Presenter: John Byrd
  • Diffuse Large B-Cell Lymphoma Oral Presentation
    Title: The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, has Preferential Activity in the ABC Subtype of Relapsed/Refractory de Novo Diffuse Large B-cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-label, Phase 2 Study
    Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Aggressive B-Cell Lymphoma
    Date/Time: Monday, December 10, 2012   Presentation Time4:45 PM
    Location: Georgia World Congress Center, Sidney Marcus Auditorium 
    Presenter: Wyndham Wilson
  • Follicular Lymphoma Oral Presentation
    Title: The Bruton's Tyrosine Inhibitor Ibrutinib (PCI-32765) is Active and Tolerated in Relapsed Follicular Lymphoma
    Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Mantle Cell Lymphoma and Follicular Lymphoma
    Date/Time: Sunday, December 9, 2012   Presentation Time5:45 PM
    Location: Georgia World Congress Center, Sidney Marcus Auditorium
    Presenter: Nathan Fowler
  • Multiple Myeloma Poster Presentation
    Title: Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory MM
    Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III
    Date/Time: Monday, December 10, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Ravi Vij
  • Non-Hodgkin's Lymphoma Poster Presentation
    Title: A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
    Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
    Date/Time: Saturday, December 8, 2012, 5:30 PM - 7:30 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Kristie Blum
  • Chronic Lymphocytic Leukemia Poster Presentation
    Title: Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death
    Session: 642. CLL - Therapy, excluding Transplantation: Poster II
    Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Mohammed Farooqui
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Poster Presentation
    Title: Ibrutinib rapidly improves platelet counts in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation
    Session: 642. CLL - Therapy, excluding Transplantation: Poster I
    Date/Time: Saturday, December 8, 2012, 5:30 PM - 7:30 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Mohammed Farooqui

Clinical ASH Presentations for HDAC Inhibitor Abexinostat (PCI-24781)

  • Follicular Lymphoma & Mantle Cell Lymphoma Oral Presentation
    Title: A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/ Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
    Session: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel Agents and Targeted Therapies
    Date/Time: Sunday, December 9, 2012   Presentation Time12:00 PM
    Location: Georgia World Congress Center, Sidney Marcus Auditorium
    Presenter:  Andrew Evens
  • Hodgkin's Lymphoma, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia  Poster Presentation
    Title: Abexinostat (S 78454), an oral Histone Deacetylase (HDAC) Inhibitor in patients with refractory or relapsed Hodgkin's Lymphoma, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I dose-escalation study in 35 patients
    Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster III
    Date/Time: Monday, December 10, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter:  F. Morschhauser

Non-Clinical ASH Presentations

  • Chronic Lymphocytic Leukemia Oral Presentation
    Title: In vivo inhibition of BCR activation in high-risk CLL patients on therapy with Bruton's tyrosine kinase inhibitor Ibrutinib: correlative studies from an ongoing Phase 2 clinical trial
    Session: 641. CLL - Biology and Pathophysiology, excluding Therapy: BCR and clone dynamics in mice and men
    Date/Time: Sunday, December 9, 2012   Presentation Time5:45 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter:  Julia Hoellenriegel
  • Chronic Lymphocytic Leukemia Oral Presentation
    Title: In Vivo Effects of Ibrutinib on BCR Signaling, Tumor Cell Activation and Proliferation in Blood and Tissue-Resident Cells of Chronic Lymphocytic Leukemia Patients
    Session: 641. CLL - Biology and Pathophysiology, excluding Therapy: BCR and clone dynamics in mice and men
    Date/Time: Session Date:  Sunday, December 9, 2012   Presentation Time:  5:30 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter: Sarah Herman
  • Chronic Lymphocytic Leukemia Oral Presentation
    Title: Global inhibition of Bruton's Tyrosine Kinase (Btk) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease
    Session: 641. CLL - Biology and Pathophysiology, excluding Therapy: BCR and clone dynamics in mice and men
    Date/Time: Sunday, December 9, 2012   Presentation Time5:00 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter: Jennifer Woyach
  • Chronic Lymphocytic Leukemia Oral Presentation
    Title: Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells
    Session: 604. Molecular Pharmacology, Drug Resistance: Therapeutic Exploitation of Oncogenic and Metabolic Pathways in Lymphoma and Leukemia
    Date/Time: Monday, December 10, 2012   Presentation Time:  6:15 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter: Jason Dubovsky
  • Hairy Cell Leukemia Poster Presentation
    Title: Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) blocks hairy cell leukemia (HCL) survival, proliferation, and BCR signaling: a new therapeutic approach for HCL
    Session: 642. CLL - Therapy, excluding Transplantation: Poster I
    Date/Time: Saturday, December 8, 2012, 5:30 PM - 7:30 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Mariela Sivina
  • B-cell Acute Lymphoblastic Leukemia Poster Presentation 
    Title: Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-cell Acute Lymphoblastic Leukemia (B-ALL)
    Session: 612. Acute Lymphoblastic Leukemia - Pathophysiology & Clinical Studies: Poster II 
    Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Ekaterina Kim
  • Chronic Lymphocytic Leukemia Poster Presentation
    Title: BTK Inhibition Targets In Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity
    Session: 642. CLL - Therapy, excluding Transplantation: Poster II
    Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Y Lynn Wang

Conference Call and further Corporate Updates

The Company will host a conference call and webcast on Wednesday, December 12, 2012, to provide an overview of the data presented at the ASH Annual Meeting and give a corporate update discussing future clinical development plans.

During the next open trading window which commences on November 7, 2012, we expect that certain employees may exercise options they hold, and sell the shares immediately following the exercise. Our CEO and Chairman, Robert W. Duggan, has advised us that he does not anticipate selling any of his shares at the present time.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

 

Pharmacyclics, Inc.

Condensed Consolidated Balance Sheets

(unaudited; in thousands)




September 30,

  2012


June 30,

2012

ASSETS










   Cash and cash equivalents

$

276,187

$

197,896

   Marketable securities


9,916


5,711

   Other current assets


11,406


9,788

      Total current assets


297,509


213,395

   Property and equipment, net


4,975


3,842

   Other assets


2,074


1,883

      Total assets

$

304,558

$

219,120






LIABILITIES AND STOCKHOLDERS' EQUITY










   Deferred revenue – current portion

$

7,978

$

8,054

   Other current liabilities


17,844


10,932

      Total current liabilities


25,822


18,986

   Deferred revenue – non-current portion


64,804


67,324

   Deferred rent


765


687

     Total liabilities


91,391


86,997

   Stockholders' equity


213,167


132,123

     Total liabilities and stockholders' equity

$

304,558

$

219,120






 

Pharmacyclics, Inc.

Condensed Consolidated Statements of Operations
(unaudited; in thousands, except per share data)




Three Months Ended

September 30,



2012


2011

Revenue:





   License and milestone revenue

$

100,000

$

-

   Collaboration services revenue


2,695


37

      Total revenue


102,695


37

Operating expenses*:





   Research and development


19,072


11,248

   General and administrative


4,868


3,350

      Total operating expenses


23,940


14,598

Income (loss) from operations


78,755


(14,561)

Interest and other income, net


52


23

Income (loss) before income taxes


78,807


(14,538)

Income tax (provision) benefit


(3,201)


-

Net income (loss)

$

75,606

$

(14,538)






Net income (loss) per share:





Basic

$

1.09

$

(0.21)

Diluted

$

1.02

$

(0.21)

Weighted average shares used to compute net income (loss) per share:





Basic


69,512


68,323

Diluted


74,456


68,323






* Includes share-based compensation as follows:










Research and development

$

2,590

$

1,538

General and administrative


576


626

Total

$

3,166

$

2,164

 

 

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)

(unaudited; in thousands, except per share data)




Three Months Ended

September 30,



2012


2011






GAAP net income (loss)

$

75,606

$

(14,538)

Adjustments:





Research & development share-based compensation(2)


2,590


1,538

General & administrative share-based compensation(2)


576


626



3,166


2,164

Non-GAAP net income (loss)

$

78,772

$

(12,374)






GAAP net income (loss) per share – basic

$

1.09

$

(0.21)

     Share-based compensation expense


0.04


0.03

Non-GAAP net income (loss) per share – basic

$

1.13

$

(0.18)

GAAP net income (loss) per share – diluted

$

1.02

$

(0.21)

     Share-based compensation expense


0.04


0.03

Non-GAAP net income (loss) per share – diluted

$

1.06

$

(0.18)



(1)

 This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance with GAAP.

(2)

All share-based compensation was excluded for the non-GAAP analysis.

SOURCE Pharmacyclics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
“In the past year we've seen a lot of stabilization of WebRTC. You can now use it in production with a far greater degree of certainty. A lot of the real developments in the past year have been in things like the data channel, which will enable a whole new type of application," explained Peter Dunkley, Technical Director at Acision, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The BPM world is going through some evolution or changes where traditional business process management solutions really have nowhere to go in terms of development of the road map. In this demo at 15th Cloud Expo, Kyle Hansen, Director of Professional Services at AgilePoint, shows AgilePoint’s unique approach to dealing with this market circumstance by developing a rapid application composition or development framework.
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud strategy and programs. In this Power Panel at 15th Cloud Expo (http://www.CloudComputingExpo.com), moderated by Ashar Baig, Research Director, Cloud, at Gigaom Research, Nate Gordon, Director of T...
"BSQUARE is in the business of selling software solutions for smart connected devices. It's obvious that IoT has moved from being a technology to being a fundamental part of business, and in the last 18 months people have said let's figure out how to do it and let's put some focus on it, " explained Dave Wagstaff, VP & Chief Architect, at BSQUARE Corporation, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Windstream, a leading provider of advanced network and cloud communications, has been named “Silver Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. Windstream (Nasdaq: WIN), a FORTUNE 500 and S&P 500 company, is a leading provider of advanced network communications, including cloud computing and managed services, to businesses nationwide. The company also offers broadband, phone and digital TV services to consumers primarily in rural areas.
The Internet of Things is not new. Historically, smart businesses have used its basic concept of leveraging data to drive better decision making and have capitalized on those insights to realize additional revenue opportunities. So, what has changed to make the Internet of Things one of the hottest topics in tech? In his session at @ThingsExpo, Chris Gray, Director, Embedded and Internet of Things, discussed the underlying factors that are driving the economics of intelligent systems. Discover how hardware commoditization, the ubiquitous nature of connectivity, and the emergence of Big Data a...

ARMONK, N.Y., Nov. 20, 2014 /PRNewswire/ --  IBM (NYSE: IBM) today announced that it is bringing a greater level of control, security and flexibility to cloud-based application development and delivery with a single-tenant version of Bluemix, IBM's platform-as-a-service. The new platform enables developers to build ap...

SYS-CON Events announced today that IDenticard will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. IDenticard™ is the security division of Brady Corp (NYSE: BRC), a $1.5 billion manufacturer of identification products. We have small-company values with the strength and stability of a major corporation. IDenticard offers local sales, support and service to our customers across the United States and Canada. Our partner network encompasses some 300 of the world's leading systems integrators and security s...
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete at launch. DevOps may be disruptive, but it is essential.
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Nigeria has the largest economy in Africa, at more than US$500 billion, and ranks 23rd in the world. A recent re-evaluation of Nigeria's true economic size doubled the previous estimate, and brought it well ahead of South Africa, which is a member (unlike Nigeria) of the G20 club for political as well as economic reasons. Nigeria's economy can be said to be quite diverse from one point of view, but heavily dependent on oil and gas at the same time. Oil and natural gas account for about 15% of Nigera's overall economy, but traditionally represent more than 90% of the country's exports and as...
The Internet of Things is a misnomer. That implies that everything is on the Internet, and that simply should not be - especially for things that are blurring the line between medical devices that stimulate like a pacemaker and quantified self-sensors like a pedometer or pulse tracker. The mesh of things that we manage must be segmented into zones of trust for sensing data, transmitting data, receiving command and control administrative changes, and peer-to-peer mesh messaging. In his session at @ThingsExpo, Ryan Bagnulo, Solution Architect / Software Engineer at SOA Software, focused on desi...
"At our booth we are showing how to provide trust in the Internet of Things. Trust is where everything starts to become secure and trustworthy. Now with the scaling of the Internet of Things it becomes an interesting question – I've heard numbers from 200 billion devices next year up to a trillion in the next 10 to 15 years," explained Johannes Lintzen, Vice President of Sales at Utimaco, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"For over 25 years we have been working with a lot of enterprise customers and we have seen how companies create applications. And now that we have moved to cloud computing, mobile, social and the Internet of Things, we see that the market needs a new way of creating applications," stated Jesse Shiah, CEO, President and Co-Founder of AgilePoint Inc., in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the industry’s first all flash version of HyperConverged Appliances that include both compute and storag...
Today’s enterprise is being driven by disruptive competitive and human capital requirements to provide enterprise application access through not only desktops, but also mobile devices. To retrofit existing programs across all these devices using traditional programming methods is very costly and time consuming – often prohibitively so. In his session at @ThingsExpo, Jesse Shiah, CEO, President, and Co-Founder of AgilePoint Inc., discussed how you can create applications that run on all mobile devices as well as laptops and desktops using a visual drag-and-drop application – and eForms-buildi...
We certainly live in interesting technological times. And no more interesting than the current competing IoT standards for connectivity. Various standards bodies, approaches, and ecosystems are vying for mindshare and positioning for a competitive edge. It is clear that when the dust settles, we will have new protocols, evolved protocols, that will change the way we interact with devices and infrastructure. We will also have evolved web protocols, like HTTP/2, that will be changing the very core of our infrastructures. At the same time, we have old approaches made new again like micro-services...
Code Halos - aka "digital fingerprints" - are the key organizing principle to understand a) how dumb things become smart and b) how to monetize this dynamic. In his session at @ThingsExpo, Robert Brown, AVP, Center for the Future of Work at Cognizant Technology Solutions, outlined research, analysis and recommendations from his recently published book on this phenomena on the way leading edge organizations like GE and Disney are unlocking the Internet of Things opportunity and what steps your organization should be taking to position itself for the next platform of digital competition.
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
As the Internet of Things unfolds, mobile and wearable devices are blurring the line between physical and digital, integrating ever more closely with our interests, our routines, our daily lives. Contextual computing and smart, sensor-equipped spaces bring the potential to walk through a world that recognizes us and responds accordingly. We become continuous transmitters and receivers of data. In his session at @ThingsExpo, Andrew Bolwell, Director of Innovation for HP's Printing and Personal Systems Group, discussed how key attributes of mobile technology – touch input, sensors, social, and ...